Cytokine therapy for craniosynostosis.

Area of Science:

• Craniofacial surgery
• Regenerative medicine
• Pediatric neurosurgery

Background:

• Craniosynostosis, premature fusion of cranial sutures, affects 300-500 per million live births.
• Surgical intervention (suturectomy) to release fused sutures is common but often leads to rapid reossification (resynostosis).
• Resynostosis causes further brain restriction and craniofacial deformities, necessitating repeat surgeries and increasing patient risk.

Purpose of the Study:

• To review recent advances in understanding craniosynostosis and developing novel therapeutic strategies.
• To explore the potential of biologically based therapies as adjuncts to surgical management.
• To reduce complications associated with surgical treatment and resynostosis.

Main Methods:

• Review of recent scientific literature on genetic mutations and the aetiopathogenesis of craniosynostosis.
• Analysis of studies on cranial suture biology and molecular pathways of suture fusion.
• Examination of advancements in tissue engineering for delivering therapeutic agents (cytokines, genes) to cranial sutures.

Main Results:

• Identification of key genetic factors and molecular mechanisms underlying craniosynostosis.
• Development of novel tissue engineering constructs and delivery vehicles for therapeutic interventions.
• Demonstration of potential for biologically based therapies to rescue fusing sutures or manage resynostosis.

Conclusions:

• Advances in bone biology and tissue engineering offer promising avenues for managing craniosynostosis.
• Biologically based therapies can serve as adjuncts to surgery, potentially preventing resynostosis.
• Targeted therapies may decrease the morbidity and mortality associated with repeated surgical interventions for craniosynostosis.